Skip to main content
. 2021 Sep 15;29(11):584–594. doi: 10.1007/s12471-021-01634-y

Fig. 2.

Fig. 2

Flowchart for the appropriateness of anticoagulant treatment for the whole population. LMWH low molecular weight heparins, NOAC non-vitamin K antagonist oral anticoagulants, VKA vitamin K antagonists

HHS Vulnerability Disclosure